Veridex of Raritan, NJ, has received US Patent No. 8,183,353, "Breast cancer prognostics." A method is claimed for assessing the likelihood of a recurrence or metastasis of breast cancer in a patient diagnosed with or treated for breast cancer. The method involves the analysis of a gene expression profile that includes up to 56 genes. Arrays to capture and indicate the presence, absence, or degree of gene expression are also described as are kits that include reagents for conducting the gene expression analysis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: issues in reproducibility, circulating DNA predicts breast cancer relapse, and more.

Because of an autoimmune disorder, a man has been shedding live polioviruses for 28 years, according to an analysis appearing in PLOS Pathogens.

Being in a long-term collaboration can increase researchers' citation rates by 17 percent, a recent analysis says.

By analyzing tweets, Canadian researchers examine the public's view of gene patenting.